139 related articles for article (PubMed ID: 20709669)
1. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.
Parikh SA; Kadia T; Jabbour E
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):301-2. PubMed ID: 20709669
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
5. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Solis EC
Curr Oncol Rep; 2011 Oct; 13(5):359-60. PubMed ID: 21755276
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Borthakur G; Cortes JE; Estey EE; Jabbour E; Faderl S; O'Brien S; Garcia-Manero G; Kadia TM; Wang X; Patel K; Luthra R; Koller C; Brandt M; Ravandi F; Kantarjian H
Am J Hematol; 2014 Oct; 89(10):964-8. PubMed ID: 24990142
[TBL] [Abstract][Full Text] [Related]
9. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
Jamy O; Bae S; Costa LJ; Erba HP; Papadantonakis N
Leuk Res; 2018 Nov; 74():64-67. PubMed ID: 30300822
[TBL] [Abstract][Full Text] [Related]
11. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; Kim JG; Sohn SK; Kim HJ
J Korean Med Sci; 2009 Jun; 24(3):498-503. PubMed ID: 19543516
[TBL] [Abstract][Full Text] [Related]
12. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Borthakur G; Kantarjian H; Wang X; Plunkett WK; Gandhi VV; Faderl S; Garcia-Manero G; Ravandi F; Pierce S; Estey EH
Cancer; 2008 Dec; 113(11):3181-5. PubMed ID: 18932257
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
Borthakur G; Ravandi F; Patel K; Wang X; Kadia T; DiNardo C; Garcia-Manero G; Pemmaraju N; Jabbour EJ; Takahashi K; Ohanian M; Daver N; Alvarado Y; Brandt M; Pierce S; Kantarjian H
Am J Hematol; 2022 Nov; 97(11):1427-1434. PubMed ID: 36053747
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
[TBL] [Abstract][Full Text] [Related]
15. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
17. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
Higashi Y; Turzanski J; Pallis M; Russell NH
Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
19. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
20. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
